IRIS
DE TURSI, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.591
EU - Europa 2.750
AS - Asia 1.382
SA - Sud America 46
AF - Africa 11
Continente sconosciuto - Info sul continente non disponibili 11
OC - Oceania 2
Totale 7.793
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.579
IE - Irlanda 672
IT - Italia 577
SG - Singapore 545
CN - Cina 480
SE - Svezia 420
UA - Ucraina 261
FR - Francia 208
TR - Turchia 172
DE - Germania 162
GB - Regno Unito 153
IN - India 110
RU - Federazione Russa 88
FI - Finlandia 60
VN - Vietnam 48
BE - Belgio 44
BR - Brasile 39
AT - Austria 28
CZ - Repubblica Ceca 18
NL - Olanda 14
EU - Europa 11
PL - Polonia 11
CA - Canada 10
EG - Egitto 6
HK - Hong Kong 6
LT - Lituania 6
RO - Romania 6
GR - Grecia 5
JP - Giappone 5
PT - Portogallo 5
ES - Italia 4
PK - Pakistan 3
CL - Cile 2
CO - Colombia 2
ID - Indonesia 2
MA - Marocco 2
PY - Paraguay 2
TW - Taiwan 2
UZ - Uzbekistan 2
AL - Albania 1
AR - Argentina 1
AU - Australia 1
BD - Bangladesh 1
BG - Bulgaria 1
BH - Bahrain 1
CH - Svizzera 1
DK - Danimarca 1
DZ - Algeria 1
IQ - Iraq 1
IR - Iran 1
KR - Corea 1
LV - Lettonia 1
MM - Myanmar 1
MT - Malta 1
MX - Messico 1
NG - Nigeria 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
Totale 7.793
Salva come PNG Salva come JPEG
Città #
Chandler 877
Dublin 648
Singapore 454
Jacksonville 446
Princeton 262
Ashburn 181
Nanjing 124
Chieti 116
Izmir 112
Dearborn 105
Wilmington 105
Southend 104
Altamura 100
Beijing 93
Santa Clara 93
Ann Arbor 89
Pescara 62
Boardman 57
Los Angeles 56
Cambridge 53
New York 48
Dong Ket 47
Brussels 43
Washington 39
Menlo Park 36
Nanchang 30
Munich 25
Shenyang 24
Helsinki 21
Norwalk 21
Falls Church 19
Hebei 19
Rome 19
Woodbridge 19
Kunming 18
Tianjin 16
Vienna 16
Houston 15
Seattle 15
Amsterdam 13
Ancona 13
Jiaxing 13
Nuremberg 13
Hangzhou 12
Brno 11
Milan 11
Edinburgh 10
Frankfurt am Main 9
Pune 9
Redwood City 9
Grevenbroich 8
Kraków 8
Changchun 7
Hefei 7
Shanghai 7
Cairo 6
Changsha 6
Guangzhou 6
Hong Kong 6
London 6
Mcallen 6
Ascoli Piceno 5
Giaveno 5
Lanciano 5
Moscow 5
Pisa 5
Shijiazhuang 5
Simi Valley 5
Tappahannock 5
Tokyo 5
L’Aquila 4
Madrid 4
Rouen 4
São Paulo 4
Zhengzhou 4
Altino 3
Ameno 3
Aprilia 3
Athens 3
Bangalore 3
Chengdu 3
Garden City 3
Islamabad 3
Jinan 3
Lanzhou 3
Montreal 3
Olomouc 3
Ottawa 3
Paris 3
Perego 3
Prague 3
Redmond 3
San Mateo 3
Sulmona 3
Toronto 3
Tucson 3
Wuhan 3
Andover 2
Antrodoco 2
Bari 2
Totale 4.960
Salva come PNG Salva come JPEG
Nome #
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 119
PERITONECTOMIA ED HIPEC NEL TRATTAMENTO DELLA CARCINOSI PERITONEALE: RISULTATI PRELIMINARI DOPO UN ANNO DI ESPERIENZA 114
The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. 112
A multicenter phase II study of Epirubicin (E) with low-dose Herceptin (LD-H) as a first line treatment in HER-2 overexpressing metastatic breast cancer (MBC): Preliminary Results 111
New Targets for Therapy in Pancreatic Cancer 109
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 104
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 101
Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer 100
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells 93
PO-1074 Radiotherapy and immuno-check point inhibitors for brain metastases. A mono-institutional analysis 93
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 93
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 90
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 90
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report 90
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 90
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 90
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 90
null 90
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 89
Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction 89
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 88
Principali effetti collaterali delle terapie mediche 86
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 85
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer 84
Speed rate (SR) as a new dynamic index of melanoma behavior 83
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study 83
ABIRATERONE ACETATE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CHEMOTHERAPY-NAIVE PATIENTS: AN ITALIAN MULTICENTER 'REAL-LIFE' 1-YEAR STUDY 82
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 81
Persistence and adherence to androgen deprivation therapy in men with prostate cancer: an administrative database study 81
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study 81
Cytokine Levels and UVr Sensitivity in HaCaT Cells and Cetuximab Treated Patients. 78
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 78
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 78
Arterial Thrombosis in ambulatory cancer patients treated with chemotherapy. 77
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 76
Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients 75
Rivaroxaban for cancer-associated cardiac thrombosis 75
A multicenter phase II study of Epirubicin with low-dose Herceptin as a first line treatment in HER-2 overexpressing metastatic breast cancer 74
Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts 74
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study 74
A real-life multicenter, retrospective analysis of Abiraterone Acetate (AA) in 340 metastatic castration-resistant prostate cancer (mCRPC) patients after chemotherapy, updated results 74
null 74
Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 73
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy(HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis ofovarian origin 72
Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: A systematic review 72
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 71
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 71
Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial 70
Real world treatment practice in patients with advanced melanoma in the nivolumab era: five novel Italian case reports and a literature review 70
Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy 69
Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A “snapshot” from clinical practice 69
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 69
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study 68
Enzalutamide in patients with castration-refractory prostate cancer: Retrospective, multicenter, real life study 67
Quantification of EGFR Mutations in Plasma of NSCLC Patients: An Early Predictor of Clinical Response to Tyrosine Kinase Inhibitor 67
Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 66
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study 66
Blood Circulating CD133+ Extracellular Vesicles Predict Clinical Outcomes in Patients with Metastatic Colorectal Cancer 65
F05Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 65
null 65
Corrigendum to "Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation" 65
Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study 65
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: A dose-finding study 64
Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 64
Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study 64
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 63
A real -life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second -line therapy 63
Peritonectomy and hyperthermic chemotherapy in patients with advanced or recurrent ephitelial ovarian cancer: a single center cohort study 63
Cabazitaxel after Docetaxel in patients with metastatic, castration-resistant, prostate cancer (mCRPC): A prospective, observational study about toxicity profile and quality of life. 62
Relationship and predictive role of the dual expression of FGFR and IL-8 in metastatic renal cell carcinoma treated with targeted agents 62
Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 61
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50 61
Phenotypic and proteomic analysis identifies hallmarks of blood circulating extracellular vesicles in NSCLC responders to immune checkpoint inhibitors 61
Epirubicin plus low-dose trastuzumab in HER2 positivemetastatic breast cancer 59
Enzalutamide in real life: Results from a retrospective, multicenter, italian study 59
Alectinib induced regression of renal and hepatic cysts caused by crizotinib 59
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study. 58
High Blood Concentration of Leukocyte-Derived Extracellular Vesicles Is Predictive of Favorable Clinical Outcomes in Patients with Pancreatic Cancer: Results from a Multicenter Prospective Study 57
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study 57
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study 57
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 56
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results 56
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer 55
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 55
Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study. 54
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 54
PO-06 Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 54
Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score 54
Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression 54
Treatment and outcome (s) of a large cohort of Italian patients (pts) with poor-risk metastatic renal cell carcinoma (prRCC) 53
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes 53
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: The multicenter “SLAVE” study 53
Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients 53
Nivolumab in Advanced Non-Squamous NSCLC Patients with KRAS Mutations: Results from the Italian Expanded Access Program (EAP) 52
Nivolumab and diabetes mellitus: safe administration in a patient with pancreatic metastases from melanoma 52
Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. 50
A multicenter phase II study of epirubicin (E) with low-dose herceptin (LD-H) as a first-line treatment in HER2 overexpressing metastatic breast cancer (MBC) 49
Outcomes of systemic therapy in relapsed renal cell carcinoma (RCC) treated with adjuvant sunitinib (AS) 49
High blood concentration of circulating cancer stem cell-derived extracellular vesicles is associated with poor survival in advanced colorectal cancer patients 49
Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review 48
Totale 7.210
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.961
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.961
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020458 0 0 0 0 0 0 0 69 71 134 168 16
2020/2021815 122 28 153 21 51 168 33 24 58 51 30 76
2021/2022803 19 28 14 193 75 26 20 43 51 20 68 246
2022/20232.328 205 323 188 257 166 411 115 216 273 23 103 48
2023/20241.042 63 32 79 34 67 394 177 43 25 35 10 83
2024/20251.293 133 454 303 68 56 125 125 29 0 0 0 0
Totale 8.513